BridgeMD
New treatment option for Idiopathic Infantile Hypercalcaemia - Severe Form
Official title Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
ClinicalTrials.gov ID: NCT03301038
What this study is testing
What is Rifampin?
Rifampin is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for idiopathic infantile hypercalcaemia - severe form.
Also referred to as Rifadin, Rifampicin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 65
You may be able to join if
- Males or females age 6 months to 65 years.
- at least one mutations of CYP24A1
- Serum and/or urinary calcium above the normal reference range for age
- Serum PTH concentration \<20 pg/ml
- Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.
You likely can't join if
- Parents/guardians or people who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
- Allergy to rifampin or related medications
- Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with...
- Pregnancy or breastfeeding
- Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:
- Aspartate Aminotransferase (AST/SGOT) \> 2.0 times the upper limit of normal Alanine aminotransferase (ALT/SGPT) \> 2.0 times the upper limit of...
The study team makes the final eligibility decision.
Where it's taking place
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 months to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.